SMOKING CESSATION THAT WORKS

OUR BUSINESS

We have developed a platform inhaler with embedded software controls that allow us to personalize the dose of medicine we deliver to our patients. We are currently leveraging this technology to develop and commercialize our lead asset, an inhaled therapy to treat smoking addiction. Over 1.2 billion people around the world are addicted to smoking and the success rate for those who attempt to quit with today's medications is less than 10%. Due to the difficulty of quitting, smoking remains the #1 cause of preventable death and disease in the world today. Miist is working to bring the first pulmonary nicotine replacement therapy (NRT) inhaler to market, offering a novel solution to one of the world's biggest public health crises.